Patents by Inventor Yuanzheng Zhang
Yuanzheng Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240084004Abstract: The present invention discloses antibodies to canine PD-I that have specific sequences and a high binding affinity for canine PD-I. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.Type: ApplicationFiled: May 8, 2023Publication date: March 14, 2024Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
-
Publication number: 20240002518Abstract: The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine EL-31 receptor alpha, and that can block the binding of canine IL-31 to canine EL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.Type: ApplicationFiled: October 14, 2021Publication date: January 4, 2024Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Anasuya Saha
-
Publication number: 20230391879Abstract: The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine IL-31 receptor alpha, and that can block the binding of canine IL-31 to canine IL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.Type: ApplicationFiled: October 14, 2021Publication date: December 7, 2023Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Anasuya Saha
-
Publication number: 20230295289Abstract: The present invention provides compositions for treating canine atopic dermatitis that comprise a fusion protein that binds canine IL-22, a caninized anti-pruritic antibody, and a caninized anti-inflammatory antibody. The present invention further provides compositions that comprise a bispecific binding partners that comprises that fusion protein and a caninized anti-pruritic antibody or a caninized anti-inflammatory antibody, or alternatively, a bispecific antibody comprising a caninized anti-pruritic antibody and a caninized anti-inflammatory antibody, which in addition comprises a fusion protein that binds canine IL-22.Type: ApplicationFiled: December 18, 2020Publication date: September 21, 2023Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Anasuya Saha
-
Publication number: 20230250177Abstract: The present invention provides compositions for treating canine atopic dermatitis that comprise a caninized anti-proliferative antibody, a caninized anti-pruritic antibody, and a caninized anti-inflammatory antibody. The present invention further relates to compositions that comprise a bispecific antibody that comprises a caninized anti -pruritic antibody and a caninized anti-proliferative antibody or alternatively a bispecific antibody comprising a caninized anti-pruritic antibody and a caninized anti-inflammatory antibody.Type: ApplicationFiled: December 18, 2020Publication date: August 10, 2023Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Anasuya Saha
-
Patent number: 11680097Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.Type: GrantFiled: June 5, 2020Date of Patent: June 20, 2023Assignee: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
-
Publication number: 20230053131Abstract: The present invention provides antibodies to canine IL-4 receptor alpha that have a highbinding affinity for canine IL-4 receptor alpha, and that can block the binding of canine IL-4 and/or IL-13 to canine IL-4 receptor alpha. The present invention further relates to epitopes of canine IL-4 receptor alpha that bind to the antibodies to canine IL-4 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.Type: ApplicationFiled: December 18, 2020Publication date: February 16, 2023Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang
-
Publication number: 20230044037Abstract: The present invention provides antibodies to canine IL-4 receptor alpha that have a high binding affinity for canine IL-4 receptor alpha, and that can block the binding of canine IL-4 and/or IL-13 to canine IL-4 receptor alpha. The present invention further relates to epitopes of IL-4 receptor alpha that bind to the antibodies to canine IL-4 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.Type: ApplicationFiled: December 18, 2020Publication date: February 9, 2023Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang
-
Publication number: 20220389114Abstract: The present invention discloses antibodies including caninized antibodies against canine PD-L1 with specific properties. The present invention further relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes. The invention further discloses the use of the caninized anti-canine PD-LI antibodies of the present invention in the treatment of cancer in dogs.Type: ApplicationFiled: August 15, 2022Publication date: December 8, 2022Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
-
Patent number: 11447561Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.Type: GrantFiled: December 18, 2019Date of Patent: September 20, 2022Assignee: Intervet, Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
-
Publication number: 20220251209Abstract: The present invention provides caninized anti-human CTLA-4 antibodies that have specific sequences and a high binding affinity for canine CTLA-4. The invention also relates to use of these antibodies in the treatment of cancer in canines and other companion animals.Type: ApplicationFiled: July 15, 2020Publication date: August 11, 2022Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
-
Publication number: 20220251208Abstract: The present invention provides caninized murine antibodies against canine CTLA-4 that have specific sequences and a high binding affinity for canine CTLA-4. The present invention further provides epitopes of canine CTLA-4 for caninized murine antibodies against canine CTLA-4.5 The invention also relates to use of these antibodies in the treatment of cancer in canines and other companion animals.Type: ApplicationFiled: July 15, 2020Publication date: August 11, 2022Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
-
Publication number: 20220204615Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.Type: ApplicationFiled: January 12, 2022Publication date: June 30, 2022Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
-
Publication number: 20220056143Abstract: The present invention provides caninized human anti-human IL-4R? antibodies that have specific sequences and a high binding affinity for canine IL-4R?. The invention also relates to use of these antibodies in the treatment of dogs against atopic dermatitis.Type: ApplicationFiled: June 30, 2021Publication date: February 24, 2022Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang
-
Patent number: 11248047Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.Type: GrantFiled: September 13, 2018Date of Patent: February 15, 2022Assignee: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
-
Patent number: 11091556Abstract: The present invention provides caninized human anti-human IL-4R? antibodies that have specific sequences and a high binding affinity for canine IL-4R?. The invention also relates to use of these antibodies in the treatment of dogs against atopic dermatitis.Type: GrantFiled: December 15, 2016Date of Patent: August 17, 2021Assignee: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang
-
Patent number: 10927172Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.Type: GrantFiled: June 13, 2018Date of Patent: February 23, 2021Assignee: INTERVET INC.Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard Presta
-
Publication number: 20210040223Abstract: The present invention discloses antibodies and blocking antibodies to canine IL-4 receptor alpha that have specific sequences and a high binding affinity for canine IL-4 receptor ?. The present invention also discloses the use of the antibodies of the present invention in the treatment of atopic dermatitis in dogs. The present invention further discloses unique epitopes that bind to the antibodies to canine IL-4 receptor alpha.Type: ApplicationFiled: October 27, 2020Publication date: February 11, 2021Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang
-
Patent number: 10858437Abstract: The present invention discloses antibodies and blocking antibodies to canine IL-4 receptor alpha that have specific sequences and a high binding affinity for canine IL-4 receptor ?. The present invention also discloses the use of the antibodies of the present invention in the treatment of atopic dermatitis in dogs. The present invention further discloses unique epitopes that bind to the antibodies to canine IL-4 receptor alpha.Type: GrantFiled: April 1, 2016Date of Patent: December 8, 2020Assignee: Intervet, Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang
-
Publication number: 20200354450Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.Type: ApplicationFiled: June 5, 2020Publication date: November 12, 2020Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey